welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson drug startup launches gastric-cancer trial
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.
The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.
The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Ileal Pouch-Anal Anastomosis Surgery: Anatomy, Postoperative Complications, and Image-Guided InterventionTotal proctocolectomy with ileal pouch-a...
-
A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Ad...Evidence supporting aspirin and resistan...
-
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal CancersPrimary Objective: - To determine whethe...
-
Bonnies Diary May 08https://jtvcancersupport.com/embed/47453...
-
Sulindac/Erlotinib Combo Tested in Patients with Familial Adenomatous PolyposisA lower duodenal polyp burden was seen a...
-
Ileal Pouch-Anal Anastomosis RegistryLittle is known about the factors that p...
-
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Pati...This is a registry-based observation...